GlassScriptPhysician profile
Jaculeen A Dano
NPI 1619005840
$4,587.04
in general payments reported to CMS, 2019-2025
25 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $276 · 2021: $76.77 · 2022: $148 · 2023: $193 · 2024: $915 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $610.18 | 2019-2025 | |
| Amgen INC. | $433.94 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $373.54 | 2019-2025 | Nemluvio, Dysport |
| Regeneron Healthcare Solutions, INC. | $370.85 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $298.10 | 2019-2020 | |
| Abbvie INC. | $293.59 | 2019-2025 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $289.25 | 2022-2025 | Sotyktu |
| Pfizer INC. | $283.09 | 2019-2025 | |
| Janssen Biotech, INC. | $219.48 | 2019-2025 | Tremfya |
| Epi Health, LLC | $218.03 | 2019 | |
| Leo Pharma INC. | $195.50 | 2019-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $191.58 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $149.83 | 2025 | Tremfya |
| Dermira, INC. | $113.24 | 2019 | |
| Lilly USA, LLC | $106.85 | 2019-2024 | Ebglyss, Taltz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $94.10 | 2020-2025 | |
| Ucb, INC. | $67.48 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $63.39 | 2019 | |
| Dermavant Sciences, INC. | $61.32 | 2023-2024 | Vtama |
| Incyte Corporation | $54.30 | 2025 | Opzelura |
| Celgene Corporation | $30.22 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $23.25 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.77 | 2025 | Zoryve |
| Pierre Fabre Pharmaceuticals, INC. | $14.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.19 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaculeen Dano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.